Cost-effectiveness analysis compares immune checkpoint inhibitors and chemotherapy in lung cancer patients, suggesting first-line options.
Pembrolizumab is a cost-effective first-line treatment for advanced NSCLC with PD-L1 TPS ≥ 50% in Japan. Nivolumab plus ipilimumab is also a viable option. Atezolizumab is the least cost-effective.
No takes yet. Share an insight, caveat, or question.
Nusawat et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: